<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00504660</url>
  </required_header>
  <id_info>
    <org_study_id>2003-0600</org_study_id>
    <nct_id>NCT00504660</nct_id>
  </id_info>
  <brief_title>6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients</brief_title>
  <official_title>Combination of 6-Thioguanine, Capecitabine, Celecoxib and Temozolomide or CCNU for Recurrent Anaplastic Glioma and Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if the combination of 6-Thioguanine,
      Xeloda (capecitabine), and Celebrex (celecoxib) with Temodar (temozolomide) or Lomustine
      (CCNU) is effective in the treatment of recurrent or progressive anaplastic glioma or
      glioblastoma multiforme in patients who have failed previous treatments. The safety of these
      combination treatment will also be studied.

      Objectives:

      1.1 To determine the efficacy, as measured by 12 month progression-free survival, of
      TEMOZOLOMIDE or CCNU with 6-THIOGUANINE followed by CAPECITABINE and CELECOXIB in the
      treatment of patients with recurrent and/or progressive anaplastic gliomas or glioblastoma
      multiforme.

      1.2 To determine the long-term toxicity of TEMOZOLOMIDE or CCNU with 6-THIOGUANINE followed
      by CAPECITABINE and CELECOXIB in recurrent anaplastic glioma or glioblastoma multiforme
      patients treated in this manner.

      1.3 To determine the clinical relevance of genetic subtyping tumors as a predictor of
      response to this chemotherapy and long term survival
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Capecitabine is a drug that damages the DNA (deoxyribonucleic acid) of tumor cells and blocks
      the function of DNA and RNA (ribonucleic acid) of tumor cells. These actions help to kill the
      tumor cells.

      Celecoxib is a drug that may help to prevent the development of some types of cancer by
      blocking a type of enzyme (COX-2) that is found in tumor cells.

      Temozolomide and CCNU are the current standard treatment for malignant brain tumors. Both
      drugs work by damaging the DNA (deoxyribonucleic acid) of tumor cells to kill these tumor
      cells.

      6-Thioguanine is a drug that helps to increase the effects of Temozolomide and CCNU on tumor
      cells.

      Depending on the previous treatment you have received, you will be treated according to Arms
      1, 2, or 3.

      If you have not received temozolomide before, you will be treated on Arm 1. If you have
      received temozolomide before but only during radiation therapy and not as chemotherapy
      afterwards and the treatment was over 6 months ago, you will be treated with temozolomide
      according to Arm 1.

      If you have not received lomustine or carmustine, you will be treated on Arm 2. If you have
      received Gliadel wafers at surgery greater than 6 months ago and have not been treated with
      lomustine or carmustine, you will be treated with CCNU according to Arm 2.

      Arm 3 will include glioblastoma multiforme patients who may be treated with either
      temozolomide or lomustine according to the above guidelines and regimens described in Arms 1
      and 2.

      Arm 1:

      Treatment will begin with 6-thioguanine taken by mouth 4 times a day (every 6 hours) for 3
      days in a row (Days 1-3). This will be followed by temozolomide taken by mouth at bedtime for
      5 days in a row (Days 4-8). After a rest period of 6 days, capecitabine and celecoxib will be
      taken by mouth twice a day (12 hours apart) for 14 days (Days 14-27). Each cycle of treatment
      on arm 1 will be 28 days.

      Arm 2:

      Treatment will begin with 6-thioguanine taken by mouth 4 times a day (every 6 hours) for 3
      days in a row (Days 1-3). This will be followed by lomustine taken by mouth at bedtime for 1
      day (Day 4). After a rest period of 1 week, capecitabine and celecoxib will be taken by mouth
      twice a day (12 hours apart) for 14 days (Days 11-24). Each cycle of treatment on arm 2 will
      take 42 days.

      Blood tests (less than 2 teaspoons) will be repeated every 2 weeks and before each new cycle
      of treatment (a total of about 2 tablespoons). The neurological exam, anticonvulsant level
      blood tests and the stool test for blood, will be repeated before every cycle on Arms 2 and 3
      (CCNU) and before every 2 cycles on Arms 1 and 3 (temozolomide). Kidney function will be
      evaluated from the blood tests before every other course. Patients taking anticoagulants
      (coumadin, warfarin) will have procedures to test the clotting ability of the blood before
      each cycle or more frequently if the doctor feels it is necessary.

      Arm 3:

      Glioblastoma Multiforme patients will be treated on Arm 3 which will include the drug regimen
      from either Arm 1 or Arm 2.

      Treatment on all arms will continue for 1 year as long as the tumor does not grow and any
      side effects are tolerable. Treatment may continue beyond one year if your doctor feels it is
      needed. During the study, you may not receive any other investigational drug or have any
      other treatment for the cancer, including surgery.

      This is an investigational study. All drugs used in this study are FDA approved and are
      commercially available. A total of 140 patients will take part in this study. All patients
      will be enrolled at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12 Month-progression-free Survival for Participants With Anaplastic Tumors</measure>
    <time_frame>12 months</time_frame>
    <description>Progression-free Survival (PFS) at 12 months measured as percentage of participants that are alive and progression-free at 12 months (anaplastic tumors). A combination of neurological examination and MRI brain scan used to define overall response or progression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6 Month Progression-free Survival for Participants With Glioblastoma</measure>
    <time_frame>6 months</time_frame>
    <description>Progression-free Survival (PFS) at 6 months measured as percentage of participants that are alive and progression-free at 6 months (glioblastoma multiforme). A combination of neurological examination and MRI brain scan used to define overall response or progression.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Anaplastic Glioma of Brain</condition>
  <condition>Glioblastoma Multiforme</condition>
  <condition>Brain Cancer</condition>
  <arm_group>
    <arm_group_label>1: Anaplastic Tumors</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anaplastic Tumors - 6-TG 80 mg/m^2 orally (PO) every 6 hours Day 1-3; Temozolomide 150 mg/m^2 PO daily Days 4-8, after 6 day rest Capecitabine 825 mg/m^2 and Celebrex 400 mg PO every 12 hours Day 14-27 for 28 day course.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: Anaplastic Tumors</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anaplastic Tumors - 6-TG 80 mg/m^2 PO every 6 hours Day 1-3, Lomustine 100 mg/m^2 PO on Day 4; Capecitabine 825 mg/m^2 PO every 12 hours Days 11-24, and Celebrex 400 mg PO every 12 hours Days 11-24.
Participants if previously received Temozolomide but not Lomustine (CCNU) will receive Lomustine; or if had Gliadel wafers and Temozolomide with radiotherapy (XRT) will receive Temozolomide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3: Glioblastoma Multiforme</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glioblastoma Multiforme - 6-TG 80 mg/m^2 PO every 6 Hours Day 1-3; Capecitabine 825 mg/m^2 PO every 12 hours Days 14-27 and Celebrex 400 mg PO every 12 hours Day 11-24; Temozolomide 150 mg/m^2 PO daily Days 4-8 OR CCNU (Lomustine) 100 mg/m2 orally Day 4 of each 42-day cycle.
Participants receive Temozolomide if not had previous treatment and if had prior CCNU. Those previously treated with Temozolomide but not CCNU receive CCNU, and those that had Gliadel and Temozolomide with XRT receive Temozolomide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Arms 1,3 = 825 mg/m^2 By Mouth (PO) Every 12 Hours on Day 14-27; Arms 2,3 = 825 mg/m^2 PO Every 12 Hours on Day 11-24.</description>
    <arm_group_label>1: Anaplastic Tumors</arm_group_label>
    <arm_group_label>2: Anaplastic Tumors</arm_group_label>
    <arm_group_label>3: Glioblastoma Multiforme</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib (Celebrex)</intervention_name>
    <description>Arms 1,3 = 400 mg PO Every 12 Hours On Day 14-27; Arms 2,3 = 400 mg PO Every 12 Hours On Day 11-24.</description>
    <arm_group_label>1: Anaplastic Tumors</arm_group_label>
    <arm_group_label>2: Anaplastic Tumors</arm_group_label>
    <arm_group_label>3: Glioblastoma Multiforme</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Arms 1,3 = 150 mg/m^2 PO Daily On Day 4-8.</description>
    <arm_group_label>1: Anaplastic Tumors</arm_group_label>
    <arm_group_label>3: Glioblastoma Multiforme</arm_group_label>
    <other_name>Temodar</other_name>
    <other_name>TMZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lomustine</intervention_name>
    <description>Arms 2,3 = 100 mg/m^2 PO on Day 4.</description>
    <arm_group_label>2: Anaplastic Tumors</arm_group_label>
    <arm_group_label>3: Glioblastoma Multiforme</arm_group_label>
    <other_name>CCNU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6-Thioguanine</intervention_name>
    <description>Arms 1,2,3 = 80 mg/m^2 PO Every 6 Hours on Day 1-3.</description>
    <arm_group_label>1: Anaplastic Tumors</arm_group_label>
    <arm_group_label>2: Anaplastic Tumors</arm_group_label>
    <arm_group_label>3: Glioblastoma Multiforme</arm_group_label>
    <other_name>Thioguanine</other_name>
    <other_name>6-TG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All patients must sign an informed consent indicating that they are aware of the
             investigational nature of this study in keeping with the policies of this hospital.

          2. Patients with histologically proven supratentorial anaplastic oligodendrogliomas,
             anaplastic mixed oligoastrocytomas anaplastic astrocytomas or glioblastoma multiforme.

          3. Patients must have unequivocal evidence for tumor recurrence or progression by MRI
             scan performed within 14 days prior to enrollment or documented recurrence by tumor
             resection. Patients must have received radiation therapy previously.

          4. Patients having undergone recent resection of recurrent or progressive tumor will be
             eligible as long as all the following conditions are met: a) Patients have recovered
             from the effects of surgery; b) Extent of residual disease (if present) has been
             documented by MRI performed no later than 72 hours after surgery or, if not possible,
             at least 4 weeks post-operative. Radiographic evidence of residual disease is not
             mandated for enrollment.

          5. The baseline on-study MRI is performed within 14 days of enrollment and on a steroid
             dosage that has been stable. If the steroid dose is increased between the date of
             imaging and the initiation of chemotherapy, a new baseline MRI is required on stable
             steroids for 7 days.

          6. Patients must be equal to or greater than 12 years old.

          7. Patients must have a Karnofsky performance status of equal to or greater than 60
             (Karnofsky Performance Scale; Appendix D).

          8. Patients must have recovered from the toxic effects of prior therapy: 4 weeks from
             prior cytotoxic therapy and/or at least two weeks from vincristine, 6 weeks from
             nitrosoureas, 3 weeks from procarbazine administration, and 1 week for non-cytotoxic
             agents, e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, etc.
             (radiosensitizer does not count). Any questions related to the definition of
             non-cytotoxic agents should be directed to the Study Chair.

          9. Patients must have adequate bone marrow function (ANC equal or greater than 1,500/mm3
             and platelet count of equal or greater than 100,000/mm3), adequate liver function
             (SGPT and alkaline phosphatase &lt;2 times normal, bilirubin &lt;1.5 mg%), and adequate
             renal function (BUN and creatinine &lt;1.5 times institutional normal) prior to starting
             therapy.

        Exclusion Criteria:

          1. Patients with a history of any other cancer (except non-melanoma skin cancer or
             carcinoma in-situ of the cervix), unless in complete remission and off of all therapy
             for that disease for a minimum of 3 years (1 year for localized prostate carcinoma
             treated by prostatectomy or irradiation) are ineligible.

          2. Patients of childbearing potential must not be pregnant or become pregnant.

          3. Patients must not have: a) active infection; b) disease that will obscure toxicity or
             dangerously alter drug metabolism; c) serious intercurrent medical illness; d) acute
             or chronic pulmonary disease, pulmonary embolus, hypertension, diabetes, metabolic
             syndrome, stroke, heart disease,myocardial infarction, angina, coronary angioplasty,
             congestive heart failure, or coronary bypass surgery; e) allergies to sulfa drugs; f)
             severe psychiatric illness; g) uncontrolled hypertension (i.e. -&gt;135/&gt;85 mm Hg) on
             three repeated measurements during the 6 weeks prior to enrollment on the study

          4. Patients must not have (continued): h) family history of premature coronary disease
             (i.e. - onset &lt; 55 years of age); i) uncontrolled hypercholesteremia [low-density
             lipoprotein cholesterol (LDL-C &gt;130]. Hypercholesteremia must be controlled for at
             least 3 months prior to enrollment on study; j) history of systemic lupus
             erythematous, family history of protein S or C deficiencies, prior heparin-induced
             thrombocytopenia, Factor V Leiden deficiencies or high homocysteine levels; k) any
             indications for ASA deficiency

          5. Patients must not have had prior treatment with Capecitabine, 5-FU or a combination of
             Temozolomide with CCNU (Lomustine) or BCNU (Carmustine). Patients who received only
             Temozolomide during radiation therapy and did not receive adjuvant chemotherapy with
             Temozolomide and/or those who received Gliadel (BCNU) wafers at surgery without
             adjuvant chemotherapy with BCNU or CCNU are eligible if 6 months has passed since the
             treatment(s).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Conrad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>U.T. M.D. Anderson's website</description>
  </link>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2007</study_first_submitted>
  <study_first_submitted_qc>July 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2007</study_first_posted>
  <results_first_submitted>December 6, 2011</results_first_submitted>
  <results_first_submitted_qc>December 6, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 11, 2012</results_first_posted>
  <last_update_submitted>December 6, 2011</last_update_submitted>
  <last_update_submitted_qc>December 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anaplastic Glioma</keyword>
  <keyword>Glioblastoma Multiforme</keyword>
  <keyword>Brain Cancer</keyword>
  <keyword>6-Thioguanine</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Celecoxib</keyword>
  <keyword>Temozolomide</keyword>
  <keyword>Xeloda</keyword>
  <keyword>Temodar</keyword>
  <keyword>TMZ</keyword>
  <keyword>CCNU</keyword>
  <keyword>6-TG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Thioguanine</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Lomustine</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: September 23, 2003 to June 15, 2009. All patients recruited at UT MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Of the 75 enrolled participants, one was excluded prior to assignment to groups. The Anaplastic Tumors Arms (Arm 1 and Arm 2) were combined for recruitment demographics and data collection.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Anaplastic Tumors</title>
          <description>6-TG 80 mg/m^2 orally (PO) every 6 hours Day 1-3; Temozolomide 150 mg/m^2 PO daily Days 4-8 OR Lomustine 100 mg/m^2 PO on Day 4; Capecitabine 825 mg/m^2 every 12 hours; and Celebrex 400 mg PO every 12 hours for 13 days for 28 day course.</description>
        </group>
        <group group_id="P2">
          <title>Glioblastoma Multiforme</title>
          <description>6-TG 80 mg/m^2 PO every 6 Hours Day 1-3; Capecitabine 825 mg/m^2 PO every 12 hours Days 14-27 and Celebrex 400 mg PO every 12 hours Day 11-24; Temozolomide 150 mg/m^2 PO daily Days 4-8 OR CCNU (Lomustine) 100 mg/m2 orally Day 4 of each 42-day cycle.
Participants receive Temozolomide if not had previous treatment and if had prior CCNU. Those previously treated with Temozolomide but not CCNU receive CCNU, and those that had Gliadel and Temozolomide with XRT receive Temozolomide.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Anaplastic Tumors</title>
          <description>6-TG 80 mg/m^2 orally (PO) every 6 hours Day 1-3; Temozolomide 150 mg/m^2 PO daily Days 4-8 OR Lomustine 100 mg/m^2 PO on Day 4; Capecitabine 825 mg/m^2 every 12 hours; and Celebrex 400 mg PO every 12 hours for 13 days for 28 day course.</description>
        </group>
        <group group_id="B2">
          <title>Glioblastoma Multiforme</title>
          <description>6-TG 80 mg/m^2 PO every 6 Hours Day 1-3; Capecitabine 825 mg/m^2 PO every 12 hours Days 14-27 and Celebrex 400 mg PO every 12 hours Day 11-24; Temozolomide 150 mg/m^2 PO daily Days 4-8 OR CCNU (Lomustine) 100 mg/m2 orally Day 4 of each 42-day cycle.
Participants receive Temozolomide if not had previous treatment and if had prior CCNU. Those previously treated with Temozolomide but not CCNU receive CCNU, and those that had Gliadel and Temozolomide with XRT receive Temozolomide.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="74"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>12 Month-progression-free Survival for Participants With Anaplastic Tumors</title>
        <description>Progression-free Survival (PFS) at 12 months measured as percentage of participants that are alive and progression-free at 12 months (anaplastic tumors). A combination of neurological examination and MRI brain scan used to define overall response or progression.</description>
        <time_frame>12 months</time_frame>
        <population>Results from TMZ and CCNU treatment arms (Anaplastic Tumor-Glioma Arms 1 &amp; 2) were combined in the final analysis because there was no statistically significant difference between them.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Recurrent Anaplastic Glioma</title>
            <description>6-TG 80 mg/m^2 orally (PO) every 6 hours Day 1-3; Capecitabine 825 mg/m^2 and Celebrex 400 mg PO every 12 hours; Arm 1 Temozolomide (TMZ) 150 mg/m^2 PO daily Days 4-8 OR Arm 2 Lomustine 100 mg/m^2 PO on Day 4; Arm 2 Participants if previously received Temozolomide but not Lomustine (CCNU) receive Lomustine; or if had Gliadel wafers and Temozolomide with radiotherapy (XRT) receive Temozolomide.</description>
          </group>
        </group_list>
        <measure>
          <title>12 Month-progression-free Survival for Participants With Anaplastic Tumors</title>
          <description>Progression-free Survival (PFS) at 12 months measured as percentage of participants that are alive and progression-free at 12 months (anaplastic tumors). A combination of neurological examination and MRI brain scan used to define overall response or progression.</description>
          <population>Results from TMZ and CCNU treatment arms (Anaplastic Tumor-Glioma Arms 1 &amp; 2) were combined in the final analysis because there was no statistically significant difference between them.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>6 Month Progression-free Survival for Participants With Glioblastoma</title>
        <description>Progression-free Survival (PFS) at 6 months measured as percentage of participants that are alive and progression-free at 6 months (glioblastoma multiforme). A combination of neurological examination and MRI brain scan used to define overall response or progression.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Participants With Glioblastoma Multiforme</title>
            <description>6-TG 80 mg/m^2 PO every 6 Hours Day 1-3; Capecitabine 825 mg/m^2 PO every 12 hours Days 14-27 and Celebrex 400 mg PO every 12 hours Day 11-24; Temozolomide 150 mg/m^2 PO daily Days 4-8 OR CCNU (Lomustine) 100 mg/m2 orally Day 4 of each 42-day cycle.
Participants receive Temozolomide if not had previous treatment and if had prior CCNU. Those previously treated with Temozolomide but not CCNU receive CCNU, and those that had Gliadel and Temozolomide with XRT receive Temozolomide.</description>
          </group>
        </group_list>
        <measure>
          <title>6 Month Progression-free Survival for Participants With Glioblastoma</title>
          <description>Progression-free Survival (PFS) at 6 months measured as percentage of participants that are alive and progression-free at 6 months (glioblastoma multiforme). A combination of neurological examination and MRI brain scan used to define overall response or progression.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 years and 3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Anaplastic Tumors</title>
          <description>6-TG 80 mg/m^2 orally (PO) every 6 hours Day 1-3; Temozolomide 150 mg/m^2 PO daily Days 4-8 OR Lomustine 100 mg/m^2 PO on Day 4; Capecitabine 825 mg/m^2 every 12 hours; and Celebrex 400 mg PO every 12 hours for 13 days for 28 day course.</description>
        </group>
        <group group_id="E2">
          <title>Glioblastoma Multiforme</title>
          <description>6-TG 80 mg/m^2 PO every 6 Hours Day 1-3; Capecitabine 825 mg/m^2 PO every 12 hours Days 14-27 and Celebrex 400 mg PO every 12 hours Day 11-24; Temozolomide 150 mg/m^2 PO daily Days 4-8 OR CCNU (Lomustine) 100 mg/m2 orally Day 4 of each 42-day cycle.
Participants receive Temozolomide if not had previous treatment and if had prior CCNU. Those previously treated with Temozolomide but not CCNU receive CCNU, and those that had Gliadel and Temozolomide with XRT receive Temozolomide.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pain-Back</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Increased intracranial pressure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Mental Status</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANEMIA</sub_title>
                <counts group_id="E1" events="16" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>HEMOGLOBIN</sub_title>
                <counts group_id="E1" events="60" subjects_affected="24" subjects_at_risk="31"/>
                <counts group_id="E2" events="88" subjects_affected="33" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>LEUKOCYTES</sub_title>
                <counts group_id="E1" events="113" subjects_affected="21" subjects_at_risk="31"/>
                <counts group_id="E2" events="124" subjects_affected="33" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="16" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>LYMPHOPENIA</sub_title>
                <counts group_id="E1" events="160" subjects_affected="21" subjects_at_risk="31"/>
                <counts group_id="E2" events="147" subjects_affected="33" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>NEUTROPHILS (ANC/AGC)</sub_title>
                <counts group_id="E1" events="70" subjects_affected="15" subjects_at_risk="31"/>
                <counts group_id="E2" events="72" subjects_affected="28" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>PLATELETS</sub_title>
                <counts group_id="E1" events="108" subjects_affected="23" subjects_at_risk="31"/>
                <counts group_id="E2" events="96" subjects_affected="31" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>BLURRED VISION</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="31"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="32" subjects_affected="15" subjects_at_risk="31"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E2" events="18" subjects_affected="14" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="28" subjects_affected="16" subjects_at_risk="31"/>
                <counts group_id="E2" events="26" subjects_affected="16" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="31"/>
                <counts group_id="E2" events="19" subjects_affected="15" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="37" subjects_affected="24" subjects_at_risk="31"/>
                <counts group_id="E2" events="48" subjects_affected="30" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGIC RHINITIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALKALINE PHOSPHATASE</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>ALT SGPT</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="31"/>
                <counts group_id="E2" events="18" subjects_affected="14" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>AST SGOT</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>BICARBONATE SERUM-LOW</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" events="12" subjects_affected="4" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>BILIRUBIN</sub_title>
                <counts group_id="E1" events="8" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="10" subjects_affected="4" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>CREATININE</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>HYPERGLYCEMIA</sub_title>
                <counts group_id="E1" events="33" subjects_affected="14" subjects_at_risk="31"/>
                <counts group_id="E2" events="47" subjects_affected="43" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>HYPOALBUMINEMIA</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="31"/>
                <counts group_id="E2" events="21" subjects_affected="13" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>HYPOCALCEMIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E2" events="18" subjects_affected="10" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>HYPONATREMIA</sub_title>
                <counts group_id="E1" events="9" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>HYPOPHOSPHATEMIA</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E2" events="20" subjects_affected="8" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>GAIT/WALKING</sub_title>
                <counts group_id="E1" events="19" subjects_affected="12" subjects_at_risk="31"/>
                <counts group_id="E2" events="18" subjects_affected="13" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>MUSCLE WEAKNESS</sub_title>
                <counts group_id="E1" events="20" subjects_affected="10" subjects_at_risk="31"/>
                <counts group_id="E2" events="45" subjects_affected="26" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>COGNITIVE DISTURBANCE</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>CONFUSION</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>MEMORY IMPAIRMENT</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="31"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>PYRAMIDAL TRACT DYSFUNCTION</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="31"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>SEIZURE</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="31"/>
                <counts group_id="E2" events="29" subjects_affected="17" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="31"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>BRUISING</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>RASH/DESQUAMATION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>THROMBOSIS/THROMBUS/EMBOLISM</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Charles A. Conrad, MD / Professor</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>713-745-1896</phone>
      <email>skang@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

